tt-01488
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2022 (NCT05275504)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase BTKANTAGONIST
BTK antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05683717 | Phase 1 | Mar 30, 2023 | Nanjing Medical University, TransThera Biosciences Co., Ltd |
| NCT05275504 | Phase 1 | Jun 30, 2022 | TransThera Biosciences Co., Ltd, University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TransThera Biosciences Co., Ltd | For profit | 2 | 2 | 1 | 2022 |
| Nanjing Medical University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1